linjc16/ctgov huggingface dataset:
The Role of Metformin and Colesevelam in Human GLP-1 Secretion

Study Overview
=================
Brief Summary
-----------------
Our primary hypothesis is that bile acid sequestrant colesevelam and the antidiabetic drug metformin potentiates the secretion of the gut hormone glucagon-like peptide 1 (GLP-1).

Official Title
-----------------
The Role of Metformin and Colesevelam in Human GLP-1 Secretion

Conditions
-----------------
Type 2 Diabetes

Intervention / Treatment
-----------------
* Drug: Colesevelam
* Drug: Metformin
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal hemoglobin BMI > 23kg/m2 HbA1c <9 % Informed concent Exclusion Criteria: Liver disease ( aspartate aminotransferase/alanine aminotransferase >2 × reference value) Chronic intestinal disease History of liver and / or gallbladder disease Nephropathy (se-creatinine >110 µM and / or albuminuria) Insulin or GLP-1-based antidiabetic treatment History of cholecystectomy or surgical resection of bowel segment BMI <23kg/m2 or BMI >35 kg/m2 Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Colesevelam<br> | Drug: Colesevelam<br> <br> |
| Experimental: Metformin<br> | Drug: Metformin<br> <br> |
| Experimental: Placebo<br> | Other: Placebo<br> <br> |
| Experimental: Colesevelam + exendin (9-39)<br> | Drug: Colesevelam<br> <br> |
| Experimental: Metformin + exendin (9-39)<br> | Drug: Metformin<br> <br> |
| Experimental: Placebo + + exendin (9-39)<br> | Other: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in the gut hormone glucagon-like peptide 1 (GLP-1) |  | 0-240 min |
A Prospective Study of Clinical Factors Affecting Disease Progression and Treatment Results of Patients With Tumors of the Prostate, Bladder and Kidney.

Study Overview
=================
Brief Summary
-----------------
Identifying clinical factors such as medication, background diseases and blood tests that effect the course of disease in cancer patients can help physicians to better decide on the patient's treatment plan. The study seeks to identify and analyze relevant clinical factors that effect the course of the disease and the results of treatment in patients with cancers of the prostate, bladder and kidney.

Conditions
-----------------
Kidney Cancer, Prostate Cancer, Bladder Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with prostate, bladder or kidney cancer that are being treated at the Meir Medical Center and are over 18 years of age. Exclusion Criteria: Patients under the age of 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Bladder, Kidney and Prostate Cancer Patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression Free Survival | Univariate analysis will be used to assess the effects of clinical factors on progression free survival. | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient overall survival | Univariate analysis will be used to assess the effects of clinical factors on overall survival. | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Kidney Cancer, Prostate Cancer, Bladder Cancer
Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension

Study Overview
=================
Brief Summary
-----------------
This study will assess the effectiveness and safety of different combination antihypertensive treatments in patients with severe hypertension

Official Title
-----------------
A Study to Evaluate the Safety and Efficacy of Valsartan/Amlodipine Compared to Lisinopril/Hydrochlorothiazide Given Once Daily for 6 Weeks is Patients With Severe Hypertension

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: valsartan/amlodipine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with severe hypertension Exclusion Criteria: History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm Liver, kidney, or pancreas disease Insulin dependent diabetes Allergy to certain medications used to treat high blood pressure Other protocol-defined inclusion/exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: valsartan/amlodipine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events and serious adverse events at each study visit for 6 weeks |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sitting and standing blood pressure measurements after 6 weeks |  |  | 
| Laboratory test data after 6 weeks |  |  | 
| Vital signs at each study visit for 6 weeks |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypertension, high blood pressure, valsartan, amlodipine
Esophageal Calibration During Laparoscopic Fundoplication Reduces Dysphagia

Study Overview
=================
Brief Summary
-----------------
Gastro esophageal reflux is the most common benign disease of the esophagus and Laparoscopic Nissen fundoplication became the standard surgical treatment of this disease. Although being almost transient postoperative dysphagia is still a common complaint following this procedure. The aim of this study is to investigate the effect of inserting a soft structured and blunt mounted 39 F orogastric tube to postoperative dysphagia.

Official Title
-----------------
Esophageal Calibration With Soft Orogastric Tube During Laparoscopic Fundoplication Reduces Postoperative Transient Dysphagia

Conditions
-----------------
Dysphagia

Intervention / Treatment
-----------------
* Device: Esophageal calibration tube


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Grade 3 or more esophagitis Hiatal hernia larger than 3 centimeters Acide suppression therapy history longer than 2 years Exclusion Criteria: Story of endoscopic mucosal resection for Barret's mucosa
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: esophageal calibration<br>Esophageal calibration tube was applied to this group of patients during laparoscopic Nissen fundoplication operation | Device: Esophageal calibration tube<br>* An orogastric calibration tube is inserted during laparoscopic Nissen fundoplication in order to secure a certain esophageal lumen for reducing postoperative dysphagia<br>* Other names: A.M.I.Gastric tube code: AGB 355;|
| No Intervention: Control<br>Standard Laparoscopic Nissen fundoplication without esophageal calibration | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| dysphagia severity score | This score system is used to assess the severity of dysphagia | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Laparoscopic Nissen fundoplication, Esophageal calibration, Postoperative dysphagia
Joint Outcome Study Continuation for Children With Severe Factor VIII Deficiency

Study Overview
=================
Brief Summary
-----------------
The original Joint Outcome Study (JOS) enrolled 65 boys with hemophilia from 16 sites nationally. The subjects were randomized to one of two arms (prophylaxis or an enhanced episode-based treatment)and were followed prospectively until the age of six. At the age of six, the proportion of children on each treatment arm who developed bone or cartilage damage as determined by X-Ray or MRI was assessed. In addition, the function and structure of the index joints (defined as knees, ankles, and elbows)were evaluated using a physical assessment scale specially designed for preschool children. The specific aim of the Joint Outcome Study Continuation (JOSC) is to extend observations of the children participating in the original JOS until the subjects reach the age of 18 years in order to determine the natural history of joint development in hemophilia and the impact of primary or secondary prophylaxis on the prevention, limitation, or reversal of hemophilic arthropathy. In addition, plasma and DNA will be collected and banked yearly for current and future studies of biomarkers and predictors of hemophilia outcomes.

Official Title
-----------------
Continuation of Children Enrolled in Protocol #95-011, 'A Randomized Prospective Study for the Prevention of Joint Disease in Children With Severe Factor VIII Deficiency'

Conditions
-----------------
Hemophilia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Enrolled in the original JOS study, A Randomized Prospective Study for the Prevention of Joint Disease in Children with Factor VIII Deficiency Written, informed consent of parent or guardian for the proposed study The local hemophilia treatment center staff must evaluate the family's participation in the original treatment protocol and determine that the family is capable of complying with the continuation protocol Exclusion Criteria: Unable or unwilling to record the study information

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the natuaral history of joint development in hemophilia and the impact of primary or secondary prophylaxis on the prevention, limitation, or reversal of hemophilic arthropathy. |  | Enrollment, age 14, and study exit at age 18 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hemophilia, Joint, Cartilage, Damage, Prophylaxis, Factor VIII, FVIII, Disease, Arthropathy